Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q3 2020 · 10-Q
Revenue$2.22M$2.22M+611.9% vs Q3 2019 Net Income$473.00K$473.00KN/M vs Q3 2019 EPS Diluted$0.01$0.01N/M vs Q3 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flowderived-$224,000N/M Free Cash Flowderived-$224,000N/M Margins · derivedGross margin56.2%
Operating margin21.3%+313.6 pt vs Q3 2019
Net margin21.3%+621.6 pt vs Q3 2019
ended Apr 30, 2020 · filed Jun 11, 2020 · 42 d after period end